Header Logo

Connection

JAFFER A AJANI to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications JAFFER A AJANI has written about Neoplasm Staging.
JAFFER A AJANI
Connection Strength
3.700
Neoplasm Staging
  1. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2021 04 01; 273(4):751-757.
    View in: PubMed
    Score: 0.266
  2. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):60-6.
    View in: PubMed
    Score: 0.150
  3. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008 Mar 01; 112(5):1020-7.
    View in: PubMed
    Score: 0.107
  4. For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens? J Clin Oncol. 2007 Sep 20; 25(27):4315-6.
    View in: PubMed
    Score: 0.104
  5. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer. 2007 Sep 01; 110(5):989-95.
    View in: PubMed
    Score: 0.104
  6. Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery. 2021 10; 170(4):1231-1239.
    View in: PubMed
    Score: 0.067
  7. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140.
    View in: PubMed
    Score: 0.064
  8. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318.
    View in: PubMed
    Score: 0.064
  9. Palliative care for advanced gastric cancer. Expert Rev Anticancer Ther. 2020 07; 20(7):575-580.
    View in: PubMed
    Score: 0.063
  10. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol. 2019 Dec; 120(8):1350-1357.
    View in: PubMed
    Score: 0.060
  11. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer. 2018 02 06; 118(3):331-337.
    View in: PubMed
    Score: 0.053
  12. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer. 2018 Jan; 21(1):1-9.
    View in: PubMed
    Score: 0.052
  13. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017 Nov; 24(12):3683-3691.
    View in: PubMed
    Score: 0.052
  14. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.052
  15. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol. 2017 08 15; 10(1):149.
    View in: PubMed
    Score: 0.052
  16. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer. 2018 Jan; 21(1):74-83.
    View in: PubMed
    Score: 0.051
  17. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016 Dec; 140(12):1345-1363.
    View in: PubMed
    Score: 0.049
  18. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016; 10(3):383-92.
    View in: PubMed
    Score: 0.046
  19. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016 Jan; 113(1):29-35.
    View in: PubMed
    Score: 0.046
  20. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. 2015; 89(6):305-10.
    View in: PubMed
    Score: 0.045
  21. Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options? J Clin Oncol. 2015 Oct 01; 33(28):3085-91.
    View in: PubMed
    Score: 0.045
  22. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81.
    View in: PubMed
    Score: 0.044
  23. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44.
    View in: PubMed
    Score: 0.042
  24. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):638-45.
    View in: PubMed
    Score: 0.039
  25. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):531-46.
    View in: PubMed
    Score: 0.038
  26. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.037
  27. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.036
  28. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51.
    View in: PubMed
    Score: 0.036
  29. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22.
    View in: PubMed
    Score: 0.035
  30. Crescendos and decrescendos: gastric and esophageal cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):811-3.
    View in: PubMed
    Score: 0.034
  31. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):830-87.
    View in: PubMed
    Score: 0.034
  32. Modern approaches to localized cancer of the esophagus. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):902-11.
    View in: PubMed
    Score: 0.034
  33. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep. 2011 Jun; 13(3):157-67.
    View in: PubMed
    Score: 0.034
  34. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 2011 Jun; 7(6):715-26.
    View in: PubMed
    Score: 0.034
  35. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother. 2011 Feb; 12(2):225-39.
    View in: PubMed
    Score: 0.033
  36. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30.
    View in: PubMed
    Score: 0.032
  37. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22.
    View in: PubMed
    Score: 0.032
  38. In the ring with a raging bull: unresectable localized esophageal carcinoma. Onkologie. 2010; 33(5):220-1.
    View in: PubMed
    Score: 0.031
  39. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009 Feb 01; 115(3):508-16.
    View in: PubMed
    Score: 0.029
  40. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. 2009; 22(1):32-41.
    View in: PubMed
    Score: 0.028
  41. Esophageal cancer. J Natl Compr Canc Netw. 2008 Oct; 6(9):818-49.
    View in: PubMed
    Score: 0.028
  42. Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. Cancer. 2008 Feb 01; 112(3):503-10.
    View in: PubMed
    Score: 0.027
  43. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol. 2007 Dec; 14(12):3290-2.
    View in: PubMed
    Score: 0.026
  44. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007 Aug; 84(2):365-73; discussion 374-5.
    View in: PubMed
    Score: 0.026
  45. New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother? J Clin Oncol. 2007 Mar 01; 25(7):906-7; author reply 908-9.
    View in: PubMed
    Score: 0.025
  46. [Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11.
    View in: PubMed
    Score: 0.025
  47. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006 Oct 01; 107(7):1475-82.
    View in: PubMed
    Score: 0.024
  48. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul; 24(4):353-7.
    View in: PubMed
    Score: 0.024
  49. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):328-47.
    View in: PubMed
    Score: 0.024
  50. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):350-66.
    View in: PubMed
    Score: 0.024
  51. Combined modality therapy of localized gastric and esophageal cancers. J Natl Compr Canc Netw. 2006 Apr; 4(4):375-82.
    View in: PubMed
    Score: 0.024
  52. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):748-54.
    View in: PubMed
    Score: 0.023
  53. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus. 2006; 19(3):152-7.
    View in: PubMed
    Score: 0.023
  54. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 01; 104(11):2365-72.
    View in: PubMed
    Score: 0.023
  55. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005 Oct 15; 104(8):1620-6.
    View in: PubMed
    Score: 0.023
  56. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005 Oct 01; 104(7):1349-55.
    View in: PubMed
    Score: 0.023
  57. Gastric cancer. Clin Adv Hematol Oncol. 2005 Feb; 3(2):118-24.
    View in: PubMed
    Score: 0.022
  58. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005; 36(2):69-76.
    View in: PubMed
    Score: 0.022
  59. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004 Aug 01; 101(3):518-26.
    View in: PubMed
    Score: 0.021
  60. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004 Jul 15; 22(14):2774-80.
    View in: PubMed
    Score: 0.021
  61. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54.
    View in: PubMed
    Score: 0.021
  62. Gastric carcinoma. Curr Oncol Rep. 2004 May; 6(3):192-8.
    View in: PubMed
    Score: 0.021
  63. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004 May 15; 22(10):1785-96.
    View in: PubMed
    Score: 0.020
  64. Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol. 2003 Oct; 4(5):413-9.
    View in: PubMed
    Score: 0.020
  65. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. 2024 Feb; 117(2):320-326.
    View in: PubMed
    Score: 0.019
  66. Esophageal cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003 Jan; 1(1):14-27.
    View in: PubMed
    Score: 0.019
  67. Gastric cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003 Jan; 1(1):28-39.
    View in: PubMed
    Score: 0.019
  68. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12.
    View in: PubMed
    Score: 0.018
  69. Proteomic profiling of key signatures from gastric lesions to early gastric cancer. EBioMedicine. 2021 Dec; 74:103744.
    View in: PubMed
    Score: 0.017
  70. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg. 2021 10 23; 108(10):1207-1215.
    View in: PubMed
    Score: 0.017
  71. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021 10 01; 274(4):544-548.
    View in: PubMed
    Score: 0.017
  72. Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. Ann Surg Oncol. 2021 Oct; 28(11):6638-6648.
    View in: PubMed
    Score: 0.017
  73. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer. Oncologist. 2021 05; 26(5):e780-e793.
    View in: PubMed
    Score: 0.017
  74. Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol. 2000 Dec; 1(5):387-98.
    View in: PubMed
    Score: 0.016
  75. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. Cancer Sci. 2020 Nov; 111(11):4205-4217.
    View in: PubMed
    Score: 0.016
  76. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg. 2021 06; 25(6):1380-1387.
    View in: PubMed
    Score: 0.016
  77. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020 Sep; 122(3):422-432.
    View in: PubMed
    Score: 0.016
  78. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16; 33(3).
    View in: PubMed
    Score: 0.015
  79. Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol. 2020 Feb 17; 18(1):39.
    View in: PubMed
    Score: 0.015
  80. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer. 2000 Jan 15; 88(2):262-7.
    View in: PubMed
    Score: 0.015
  81. Linitis Plastica: a Distinct Type of Gastric Cancer. J Gastrointest Surg. 2020 05; 24(5):1018-1025.
    View in: PubMed
    Score: 0.015
  82. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer. 1999 Nov 01; 86(9):1657-68.
    View in: PubMed
    Score: 0.015
  83. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol. 1999 Aug; 17(8):2403-11.
    View in: PubMed
    Score: 0.015
  84. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26(11):3602-3610.
    View in: PubMed
    Score: 0.015
  85. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009 Jul; 7(7):712-47.
    View in: PubMed
    Score: 0.015
  86. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295.
    View in: PubMed
    Score: 0.014
  87. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg. 2018 11; 22(11):2013-2019.
    View in: PubMed
    Score: 0.014
  88. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018 Jun; 117(8):1721-1728.
    View in: PubMed
    Score: 0.014
  89. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018 Jul; 118(1):61-67.
    View in: PubMed
    Score: 0.014
  90. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol. 2018 Jul; 25(7):2012-2017.
    View in: PubMed
    Score: 0.014
  91. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg. 2018 08; 22(8):1325-1333.
    View in: PubMed
    Score: 0.014
  92. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018 07; 156(1):406-413.e3.
    View in: PubMed
    Score: 0.013
  93. Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol. 2018 Mar; 117(4):678-684.
    View in: PubMed
    Score: 0.013
  94. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg. 2017 Oct; 21(10):1563-1570.
    View in: PubMed
    Score: 0.013
  95. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2017 Sep; 24(9):2679-2687.
    View in: PubMed
    Score: 0.013
  96. Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol. 2017 Feb 07; 23(5):751-762.
    View in: PubMed
    Score: 0.012
  97. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382.
    View in: PubMed
    Score: 0.012
  98. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol. 2017 Apr; 24(4):960-965.
    View in: PubMed
    Score: 0.012
  99. Final Results of NRG Oncology RTOG 0246: An?Organ-Preserving Selective Resection Strategy in?Esophageal Cancer Patients Treated with Definitive?Chemoradiation. J Thorac Oncol. 2017 02; 12(2):368-374.
    View in: PubMed
    Score: 0.012
  100. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol. 2016 Oct; 114(5):602-606.
    View in: PubMed
    Score: 0.012
  101. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol. 2016 12; 23(13):4332-4337.
    View in: PubMed
    Score: 0.012
  102. Laparoscopic staging for gastric cancer. Surgery. 1996 Jun; 119(6):611-4.
    View in: PubMed
    Score: 0.012
  103. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology. 2016; 90(5):239-47.
    View in: PubMed
    Score: 0.012
  104. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1.
    View in: PubMed
    Score: 0.012
  105. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol. 2016 Feb; 23(2):626-32.
    View in: PubMed
    Score: 0.011
  106. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. 2016 Jan; 23(1):156-62.
    View in: PubMed
    Score: 0.011
  107. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer. 2015 Jun; 46(2):109-17.
    View in: PubMed
    Score: 0.011
  108. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995 Mar-Apr; 19(2):216-20.
    View in: PubMed
    Score: 0.011
  109. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology (Williston Park). 1994 Sep; 8(9):37-42; discussion 44-5, 50-2, 61.
    View in: PubMed
    Score: 0.011
  110. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6.
    View in: PubMed
    Score: 0.010
  111. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
    View in: PubMed
    Score: 0.010
  112. Concordance of studies for nodal staging is prognostic for worse survival in esophageal cancer. Dis Esophagus. 2014 Nov-Dec; 27(8):770-6.
    View in: PubMed
    Score: 0.010
  113. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012 Nov; 48(16):2941-53.
    View in: PubMed
    Score: 0.009
  114. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut. 2013 Aug; 62(8):1100-11.
    View in: PubMed
    Score: 0.009
  115. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3.
    View in: PubMed
    Score: 0.009
  116. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1967-72.
    View in: PubMed
    Score: 0.008
  117. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1.
    View in: PubMed
    Score: 0.008
  118. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol. 2009 Dec; 22(12):1612-21.
    View in: PubMed
    Score: 0.007
  119. Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8.
    View in: PubMed
    Score: 0.007
  120. NCCN practice guidelines for upper gastrointestinal carcinomas. National Comprehensive Cancer Network. Oncology (Williston Park). 1998 Nov; 12(11A):179-223.
    View in: PubMed
    Score: 0.007
  121. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11.
    View in: PubMed
    Score: 0.007
  122. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70.
    View in: PubMed
    Score: 0.007
  123. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007 Nov; 31(11):1719-25.
    View in: PubMed
    Score: 0.007
  124. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007 Jul; 14(7):2010-7.
    View in: PubMed
    Score: 0.006
  125. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67.
    View in: PubMed
    Score: 0.006
  126. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 01; 12(15):4598-604.
    View in: PubMed
    Score: 0.006
  127. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006 Jun; 1(5):478-86.
    View in: PubMed
    Score: 0.006
  128. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9.
    View in: PubMed
    Score: 0.006
  129. Neuroendocrine tumors. J Natl Compr Canc Netw. 2006 Feb; 4(2):102-38.
    View in: PubMed
    Score: 0.006
  130. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20.
    View in: PubMed
    Score: 0.006
  131. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005 May; 79(5):1716-23.
    View in: PubMed
    Score: 0.006
  132. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005 Mar 15; 11(6):2229-36.
    View in: PubMed
    Score: 0.005
  133. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1386-93.
    View in: PubMed
    Score: 0.005
  134. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7.
    View in: PubMed
    Score: 0.005
  135. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):656-63.
    View in: PubMed
    Score: 0.005
  136. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer. 2005; 8(1):18-28.
    View in: PubMed
    Score: 0.005
  137. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71.
    View in: PubMed
    Score: 0.005
  138. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93.
    View in: PubMed
    Score: 0.005
  139. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85.
    View in: PubMed
    Score: 0.005
  140. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
    View in: PubMed
    Score: 0.005
  141. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
    View in: PubMed
    Score: 0.005
  142. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004; 17(1):38-43.
    View in: PubMed
    Score: 0.005
  143. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
    View in: PubMed
    Score: 0.005
  144. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol. 2002 Aug; 80(4):181-5.
    View in: PubMed
    Score: 0.005
  145. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):34-7.
    View in: PubMed
    Score: 0.004
  146. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999 May; 51(2):153-60.
    View in: PubMed
    Score: 0.004
  147. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):1025-9.
    View in: PubMed
    Score: 0.003
  148. Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):197-204.
    View in: PubMed
    Score: 0.003
  149. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. Cancer. 1993 Jun 01; 71(11):3690-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.